Matinas BioPharma, a small biotech firm, is abandoning drug development to pivot into modular nuclear reactors through a merger with GH Power. The deal, expected to close in the fourth quarter, would leave Matinas shareholders with roughly 9% of the newly formed public parent company, GH Power International, which would list on the NYSE American exchange.
The announcement marks a dramatic shift for Matinas, which had been focused on developing treatments for serious infections. The company is also selling its remaining biotech assets, including its lead drug candidate MAT2203, to private drugmaker Azurity Pharmaceuticals for $4 million in cash, plus up to $17.5 million in milestone payments and mid-single-digit royalties.
How the Deal Is Structured
Under the terms of the definitive business combination, both Matinas and GH Power will become subsidiaries of the newly created GH Power International. The ownership split is heavily skewed toward GH Power's current owners, who are expected to hold about 91% of the combined entity. Matinas shareholders will receive the right to 0.1 share of the parent for each Matinas share they own.
This structure means that Matinas stock will trade less like a biotech company and more like a contingent claim on the merger's success. In plain terms, the share price will move primarily on news about whether the deal will close, rather than on Matinas' pipeline or broader nuclear industry trends.
Why the Pivot to Nuclear?
GH Power is a developer of modular nuclear reactors, a technology that has attracted growing investor interest as a potential source of clean, reliable energy. Modular reactors are smaller, factory-built units that can be deployed more quickly and cheaply than traditional large-scale nuclear plants. This sector has seen a surge in attention, with companies like Holtec Nuclear filing for an IPO as investor appetite for atomic power rises.
For Matinas, the move represents a complete departure from its core business. The biotech had been struggling to advance its pipeline, and the cash from the Azurity sale provides some liquidity, but the merger's success hinges on GH Power's ability to execute its nuclear plans.
What It Means for Investors
The merger is far from guaranteed. It is subject to several conditions: approval from an Ontario court, shareholder votes from both companies, GH Power raising at least $15 million in financing, and the NYSE American approving the new listing. Until these boxes are checked, the deal remains uncertain.
That uncertainty was reflected in Monday's premarket trading, where Matinas shares fell 28.6% as investors repriced the odds of the deal closing. For current Matinas shareholders, the stock has become a high-risk bet on the merger's completion. If the deal falls through, the shares could lose most of their value, as the underlying biotech business is being sold off.
For investors considering the new GH Power International, the key factors to watch will be the company's ability to secure the required financing and regulatory approvals. The nuclear sector is capital-intensive and faces long development timelines, so patience will be essential. The broader trend of AI-driven energy demand could boost interest in nuclear power, but GH Power must first prove it can deliver.
What's Next
Investors should monitor the progress of the Ontario court process, shareholder votes, and GH Power's fundraising efforts. Any news on these fronts could trigger significant moves in Matinas' stock price. The deal is expected to close in the fourth quarter, but delays or failures at any stage could derail it entirely.
For those holding Matinas shares, the 0.1-share conversion means the stock is essentially a binary bet on the merger. It's not a play on nuclear energy or biotech—it's a play on deal execution. As with any contingent-claim stock, headlines about financing or approvals can have an outsized impact, similar to Monday's sharp premarket swing.
